A simple urine test could accurately show the recurrence of kidney cancer at an early stage, potentially sparing patients ...

Several biomarker tests have been available for over a decade, with extensive research backing their effectiveness. Yet, many ...

CNW/ - Nanostics Inc., a precision health company developing diagnostic tests with its ClarityDX® platform technology, has ...

The first patient was enrolled this month in a Nanostics-sponsored clinical utility study in Calgary to quantify the impact of incorporating ClarityDX Prostate into the standard ...

The Nanostics-sponsored study will recruit 1,074 patients from two Alberta Urology sites, with Dr. Eric Hyndman serving as ...

Patients with suspected colovesical fistula often undergo a series of expensive diagnostic tests and procedures, each of which have limitations. No consensus exists on the best approach to diagnosis.

This innovative bladder cancer diagnostic kit uses urine samples to achieve 88.8 % sensitivity, promising early detection and reducing the need for cystoscopies.